Subject: CIIX Sub Launches Six New Hemp-Infused Skincare Products

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
CIIX Sub Launches Six New Hemp-Infused Skincare Products
Hot Stock to WatchHot Stock to Watch

Company:, Inc. (OTCQB: CIIX)


Price: 0.30

Change (%): - 0.01 (3.23)

Volume: 11,900
CIIX Chart Inc. Announces CBD Biotech, Inc.’s Launch of Six New Hemp-Infused Skincare Products, Complimenting its Current Skincare Lines, Designed to Increase Brand Loyalty and Awareness

SAN GABRIEL, California, Sept. 9, 2019 /PRNewswire/ —, Inc. (OTCQB: CIIX) (the “Company”), a premier provider of financial news and education for the Chinese-speaking community announced today that its subsidiary, CBD Biotech, Inc., an exempted company with limited liability incorporated in the Cayman Islands (“CBD Biotech) throughout the months of March and April 2019, launched six new-products in conjunction with its long-term strategic plans to the expand its hemp/CBD skincare offerings. After evaluating consumers’ initial reception, the new products have been well received.

“With the launch of these new hemp-infused skincare products, CBD Biotech is increasing its brand awareness and gaining customer loyalty. We expect to continue this momentum with the anticipated launch of three additional skincare products before the end of 2019. As a first mover in the CBD skincare industry in China, we are encouraged by U.S. market trends in the last year, which we believe strengthens the overall acceptance of CBD, including the passage of the 2018 Farm Bill which authorizes the sale of many CBD products, including skin-care and cosmetic products, and the recently announced acquisition of Lord Jones (private) by Cronos Group (NASDAQ: CRON) for $300 million. We believe we are moving in the right direction, in the right markets,” says Alex Hamilton, Chief Financial Officer of CBD Biotech, Inc.

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks